文献速递腹部技术与安全PETCT

转移性胃癌中[18F]FDG PET/CT表现与claudin 18.2表达的关系

Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer.
PubMed 文献 · Eur Radiol · 2024-11-21

该回顾性研究分析163例转移性胃癌患者的[18F]FDG PET/CT图像与免疫组化CLDN18.2表达,发现CLDN18.2阴性肿瘤的中位SUVmax(13.2)高于阳性肿瘤(7.55),差异有统计学意义(p < 0.001);以SUVmax 10.9为界值预测CLDN18.2表达的准确率为69.9%。结论提示[18F]FDG摄取相对较低与CLDN18.2阳性表达相关,PET/CT可能有助于预测CLDN18.2状态。

要点

  • CLDN18.2阴性转移性胃癌的中位SUVmax为13.2,高于阳性者的7.55(p < 0.001)。
  • CLDN18.2阴性肿瘤的中位TLG为231.6,高于阳性者的81.14(p = 0.001)。
  • 以SUVmax 10.9为界值预测CLDN18.2表达的准确率为69.9%。

核心结论

  • 转移性胃癌中[18F]FDG摄取相对降低与CLDN18.2阳性表达相关,[18F]FDG PET/CT可能有助于预测CLDN18.2状态并辅助治疗决策。

研究设计与样本

  • 回顾性分析163例转移性胃癌患者的[18F]FDG PET/CT图像,采用免疫组化评估CLDN18.2表达,并以厂商软件三维模式计算SUVmax、MTV和TLG。

关键影像表现/征象

  • CLDN18.2阴性肿瘤中位SUVmax为13.2(范围1.8-46.7),阳性肿瘤为7.55(范围2.3-34.8),差异有统计学意义(p < 0.001)。
  • CLDN18.2阴性肿瘤中位TLG为231.6,高于阳性肿瘤的81.14,提示代谢活性更高(p = 0.001)。

诊断标准与关键数值

  • 多因素分析提示SUVmax与CLDN18.2状态仍显著相关(p = 0.01)。
  • 以SUVmax 10.9为界值预测CLDN18.2表达,准确率为69.9%。

临床应用与阅片要点

  • 阅片时可关注转移性胃癌病灶的[18F]FDG摄取程度,SUVmax相对较低可能提示CLDN18.2阳性表达。
  • SUVmax 10.9可作为预测CLDN18.2状态的参考界值,准确率为69.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: Given that claudin 18.2 (CLDN18.2) is a cell surface protein specifically expressed by gastric cancer cells, anti-CLDN18.2 antibodies have demonstrated significant antitumor effects in patients with advanced gastric adenocarcinoma. The correlation of [18F]FDG PET/CT with CLDN18.2 expression remains unexplored. This study aimed to investigate whether CLDN18.2 expression was associated with [18F]FDG uptake and whether [18F]FDG PET/CT can be used to predict the CLDN18.2 status of gastric cancer.

METHODS: A retrospective analysis of [18F]FDG PET/CT images from 163 patients diagnosed with metastatic gastric cancer was conducted, and the expression of CLDN18.2 was assessed immunohistochemically. SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated in 3D mode using vendor-provided software. The relationship between PET metabolic parameters and CLDN18.2 status was analyzed.

RESULTS: CLDN18.2-negative tumors showed a higher median SUVmax of 13.2 (1.8-46.7) compared to CLDN18.2-positive tumors at 7.55 (2.3-34.8), with a significant difference (p < 0.001). The median TLG was significantly higher in CLDN18.2-negative tumors (231.6) than in CLDN18.2-positive ones (81.14), indicating greater metabolic activity (p = 0.001). Multivariate analysis suggested that SUVmax remained significantly correlated with the status of CLDN18.2 (p = 0.01). CLDN18.2 expression was predicted with an accuracy of 69.9% when the SUVmax value of 10.9 was used as a cutoff point for analysis.

CONCLUSION: Relatively reduced [18F]FDG uptake in metastatic gastric cancers correlates with positive CLDN18.2 expression compared to those with negative CLDN18.2 expression. [18F]FDG PET/CT may be useful for predicting the CLDN18.2 status of gastric cancer and thus aid in optimal treatment decisions.

KEY POINTS: Question The study resolves the clinical issue of determining the correlation between [18F]FDG PET/CT imaging and claudin 18.2 expression in metastatic gastric cancer. Findings Claudin 18.2-positive metastatic gastric cancers exhibit relatively lower [18F]FDG uptake than negative ones. The SUVmax of 10.9 moderately predicts claudin 18.2 expression. Clinical relevance [18F]FDG PET/CT imaging could be a noninvasive way to predict claudin 18.2 status in metastatic gastric cancer, helping to improve personalized treatment plans.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yin H, Luo R, Lv J, et al. Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer. Eur Radiol. 2024. PMID: 39572448. doi:10.1007/s00330-024-11186-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。